Core Viewpoint - The company reported its 2025 annual performance, showing a slight decline in revenue and net profit, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, remaining stable compared to the same period last year [1] - The net profit attributable to the parent company was -16.97 million yuan, and the net profit after deducting non-recurring gains and losses was -79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Regulatory Impact - The value-added tax rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] Stock Incentive Plan - The company reversed previously accrued share-based payment expenses due to not meeting the performance assessment targets of the 2023 restricted stock incentive plan [1] - Additionally, the company, based on a principle of prudence, reversed part of the previously recognized deferred tax assets, leading to an increase in income tax expenses [1]

Core Viewpoint - The company reported its 2025 annual performance, showing stable revenue but a net loss, primarily impacted by tax rate changes and performance-related adjustments [1] Financial Performance - The company achieved operating revenue of 1.378 billion yuan, which is approximately flat compared to the same period last year [1] - The net profit attributable to the parent company was a loss of 16.97 million yuan, while the net profit after deducting non-recurring gains and losses was a loss of 79.36 million yuan, both showing a reduction in losses compared to the previous year [1] Tax and Financial Adjustments - The VAT rate for the company's biological products increased from 3% to 13%, significantly adversely affecting overall revenue and profitability [1] - Due to not meeting the performance assessment targets for the 2023 restricted stock incentive plan, the company reversed previously accrued share-based payment expenses at the end of the reporting period [1] - The company also reversed part of the previously recognized deferred tax assets based on a principle of prudence, leading to an increase in income tax expenses [1] Operational Factors - The company actively expanded its innovative business and overseas markets, resulting in a year-on-year increase in related sales expenses [1] - The company continued to strengthen budget management, improving research and operational efficiency, with a slight year-on-year decrease in research and management expenses after excluding the impact of reversed share-based payment expenses [1]

Group 1 - The company expects to turn a profit in the fiscal year 2025, with significant changes in the internal and external operating environment impacting performance [1] - The company communicated with the accounting firm regarding the performance forecast, and there were no major discrepancies in the disclosed forecast data [1] - The anticipated performance change is primarily due to the failure to meet performance targets for the first and second phases of the employee stock ownership plan, leading to a reversal of previously recognized stock payment expenses amounting to 115.27 million yuan, which will positively impact the net profit attributable to shareholders by approximately 97.98 million yuan after tax effects [1]

Core Viewpoint - Changlan Technology (002879) expects a net profit attributable to shareholders of 130 million to 160 million yuan for 2025, representing a year-on-year growth of 74.07% to 114.24% [1] Group 1: Performance Forecast - The company anticipates significant changes in the internal and external operating environment affecting its performance [1] - The first and second phases of the employee stock ownership plan did not meet performance assessment targets, and it is expected that the third phase will also not meet the targets [1] Group 2: Financial Impact - According to the accounting standards, if the performance conditions for equity instruments are not met, the cumulative share-based payment expenses will be reversed in the current period [1] - The company will reverse 115 million yuan in the current period, and after considering the impact of income tax, the net profit attributable to shareholders is expected to be affected by approximately 97.976 million yuan [1]